文献速递系统性红斑狼疮

凝溶胶蛋白:与HDL-c相关的SLE疾病活动性新生物标志物

Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究通过HDL颗粒蛋白质组学分析,在9例临床缓解期SLE患者、其 flare 时及9例健康对照中筛选差异蛋白,并在104例SLE女性、46例健康女性及14例flare患者中验证。发现SLE患者血浆凝溶胶蛋白(pGSN)水平降低,与疾病活动性相关,且抗疟药治疗和高HDL胆固醇与较高pGSN水平相关。

要点

  • SLE患者pGSN水平低于健康对照,flare时进一步降低。
  • pGSN水平与HDL胆固醇水平呈正相关。
  • 抗疟药治疗患者pGSN水平显著高于未治疗者。

核心结论

  • pGSN降低与SLE患者临床疾病活动性相关。
  • 抗疟药治疗和HDL胆固醇与较高pGSN水平相关。

研究设计与样本

  • 对9例临床缓解期SLE患者(flare时)及9例健康对照的纯化HDL进行定量蛋白质组学分析(TMT标记和nanoLC-Orbitrap)。
  • 在104例SLE女性、46例健康女性及14例SLE flare患者中通过Western blot和ELISA验证候选蛋白。

主要发现

  • 与对照组相比,发现17个蛋白 fold-change >1.1。
  • SLE flare与缓解期相比,C4、Indian Hedgehog蛋白、S100A8和凝溶胶蛋白4个蛋白 fold-change 显著。
  • 104例SLE患者pGSN水平为176.02(74.9) mcg/l,低于对照组的217.13(86.7) mcg/l,P=0.005。
  • SLE患者flare时pGSN水平为104.84(41.7) mcg/l,P=0.002。
  • pGSN与HDL胆固醇相关(r=0.316,P<0.001);抗疟药治疗者pGSN为214.56(88.94) mcg/l,未治疗者为170.35(66.36) mcg/l,P=0.017。

临床怎么用

  • pGSN可作为评估SLE疾病活动性的潜在生物标志物。
  • 抗疟药治疗与较高pGSN水平相关,支持其临床使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify potential biomarkers of disease activity analysing the proteome of high-density lipoprotein (HDL) particles from SLE patients in clinical remission and when they develop a flare compared with a healthy control group. METHODS: Quantitative proteomic analyses of purified HDL were performed using Tandem Mass Tag isobaric tag-labelling and nanoLC-Orbitrap (nLC-MS/MS) from nine SLE patients in clinical remission when they developed a flare and from nine healthy controls (9-9-9). We verified the identified proteins by Western blot and ELISA in a cohort of 104 SLE women patients, 46 healthy women and 14 SLE patients when a flare developed. RESULTS: We found 17 proteins with a significant fold-change (>1.1) compared with the control group. In lupus patients experiencing a flare compared with those in remission, we identified four proteins with a significant fold-change (C4, Indian Hedgehog protein, S100A8 and gelsolin). Plasma gelsolin (pGSN) levels were decreased in the 104 SLE patients (176.02(74.9) mcg/l) compared with the control group (217.13(86.7) mcg/l); P=0.005 and when they developed a clinical flare (104.84(41.7) mcg/l); P=0.002). pGSN levels were associated with HDL cholesterol levels (r = 0.316, P<0.001). Antimalarial treated patients showed significant higher levels of pGSN (214.56(88.94) mcg/l regarding 170.35(66.36) mcg/l); P = 0.017. CONCLUSION: Decreased pGSN are associated with clinical disease activity in SLE patients. Antimalarial treatment and HDL cholesterol are associated with higher levels of pGSN.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Parra S, Heras M, Herrero P, et al. Gelsolin: a new biomarker of disease activity in SLE patients associated with HDL-c. Rheumatology (Oxford). 2020. PMID: 31504936. doi:10.1093/rheumatology/kez293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。